Screening of Ginsenoside Adjuvant with Therapeutic Human Papillomavirus-16 Recombinant Vaccine

OBJECTIVE To screen different ginsenosides as candidate adjuvant on therapeutic human papillomavirus-16 (HPV16) recombinant vaccine by comparing their effect on immune response. METHODS Five ginsenosides(Rb1, Rh1-1, Rh1-2, Rg1, Rg3) were selected and immunized with HPV16 recombinant vaccine on C57BL/6 mice. The level of cellular immune responses was detected by ELISPOT in mice, and the effect of ginsenosides on tumor growth inhibition of HPV16 recombinant vaccine was observed. RESULTS Ginsenosides Rg1 and Rb1 could significantly increase the specific cellular immune response of therapeutic HPV16 recombinant vaccine (HPV+Rg1 group vs HPV group:t=3.729, P=0.006; HPV+Rb1 group vs HPV group:t=3.204, P=0.013) and higher tumor growth inhibition in week four (HPV+Rg1 group vs HPV group:t=2.318, P=0.032; HPV+Rb1 group vs HPV group:t=2.258, P=0.037). CONCLUSION The ginsenosides Rg1 and Rb1 can improve the specificity immune effect of HPV16 recombinant vaccine in C57BL/6 mice, and maybe can become candidate adjuvants.